0RAD.LSE OSE Immunotherapeutics S.A.
- Market cap
- EUR 53.8M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2021.
Is 0RAD.LSE undervalued?
Graham numberThe Graham number of OSE Immunotherapeutics S.A. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
OSE Immunotherapeutics S.A. fundamental analysis
No fundamental analysis for OSE Immunotherapeutics S.A. yet.
OSE Immunotherapeutics S.A. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About OSE Immunotherapeutics S.A.
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. The company's products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE…
Full company profileOSE Immunotherapeutics S.A. financial statements
OSE Immunotherapeutics S.A. annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 383K | 6.68M | 24.5M | 26.0M | 10.4M | - |
| Operating Income | 17.5M | -12.6M | 4.85M | -1.47M | -19.0M | - |
| Net Income | 20.7M | -10.5M | 5.49M | -4.65M | -16.6M | - |
| Balance Sheet | ||||||
| Total Assets | 89.5M | 77.4M | 76.9M | 88.9M | 97.0M | - |
| Total Liabilities | 25.0M | 21.9M | 15.1M | 30.4M | 35.6M | - |
| Shareholders' Equity | 64.5M | 55.4M | 61.8M | 58.5M | 61.4M | - |
| Cash & Short-term Investments | 17.8M | 12.5M | 12.4M | 25.8M | 29.4M | - |
| Total Debt | 1.20M | 4.30M | 3.83M | 10.6M | 18.9M | - |
| Cash Flow | ||||||
| Operating Cash Flow | 684K | -8.00M | 1.08M | 9.14M | -19.6M | -9.92M |
| Capital Expenditure | 30.0K | 353K | 593K | 336K | 210K | 472K |
| Ratios | ||||||
| ROE | 32.0% | -18.9% | 8.9% | -7.9% | -27.0% | - |
| ROA | 23.1% | -13.6% | 7.1% | -5.2% | -17.1% | - |
| Net Profit Margin | 5,395.8% | -157.2% | 22.4% | -17.9% | -158.7% | - |
| Debt to Equity | 0.02x | 0.08x | 0.06x | 0.18x | 0.31x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
OSE Immunotherapeutics S.A. dividends
OSE Immunotherapeutics S.A. has not paid dividends in the last 9 fiscal years.
Who owns OSE Immunotherapeutics S.A.
- Insiders 25.38%
- Institutions 2.70%
- Public & others 71.92%
- Shares outstanding 14.6M
- Free float 17.3M
OSE Immunotherapeutics S.A. company profile
- Company name
- OSE Immunotherapeutics S.A.
- Ticker
- 0RAD.LSE
- ISIN
- FR0012127173
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 64
- Fiscal year end
- December
- Address
- 22, boulevard Benoni Goulin, Nantes, France, 44200
- Phone
- 33 2 28 29 10 10
- Website
- ose-immuno.com
About OSE Immunotherapeutics S.A.
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. The company's products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren's Syndrome; and FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis. The company is also developing BI 765063, which is in Phase I clinical trial to treat solid tumors; ABBV-230, an agonist antibody against ChemR23 to resolve chronic inflammation; and CLEC-1, a therapeutic target in immune-oncology and identified monoclonal antibody antagonists; and BiCKI, a new technology of bispecific checkpoint inhibitors targeting the PD1 receptor and other innovative targets. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, ARCAGY-GINECO, Foundation FoRT, and Nantes University Hospital; and Boehringer Ingelheim, MabSilico, CKD, Servier, Veloxis Pharmaceuticals, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA was founded in 2012 and is headquartered in Nantes, France.
OSE Immunotherapeutics S.A. management
9- Mr. Marc Le BozecCEO & Director · born 1969
- Mr. Thomas GidoinDeputy CEO & CFO · born 1983
- Ms. Aurore MorelloChief Scientific Officer
- Dr. Alain Chatelin M.D.Medical Director
- Bérangère Vasseur M.D.Chief Medical Officer Immuno-Oncology
- Mr. Julien PerrierChief Commercial Officer
- Ms. Linda Lebon M.Sc.Chief Regulatory Officer · born 1967
- Dr. Silvia Comis M.D.Chief Clinical & Medical Research Officer
- Mr. Jean-Jacques A.P. Mention Ph.D.Chief Business Officer